Intelligent Bio Solutions Inc. announced the submission of a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System on December 18, 2024. This non-invasive, sweat-based technology boasts 94.1% accuracy and aligns closely with blood-based drug detection.The submission marks a crucial step towards the company's goal of entering the US market in 2025. The system, already adopted in international markets, offers rapid results, cost savings, and operational efficiencies. Its potential applications span safety-critical industries, law enforcement, drug rehabilitation, and forensics.CEO Harry Simeonidis emphasized the significance of this milestone and the company's readiness to transform the drug screening market. The system's ability to detect drugs within 10 minutes positions INBS for potential revenue growth and market expansion in one of the world's largest drug screening markets.

Intelligent Bio Solutions Inc. announced the submission of a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System on December 18, 2024. This non-invasive, sweat-based technology boasts 94.1% accuracy and aligns closely with blood-based drug detection.The submission marks a crucial step towards the company's goal of entering the US market in 2025. The system, already adopted in international markets, offers rapid results, cost savings, and operational efficiencies. Its potential applications span safety-critical industries, law enforcement, drug rehabilitation, and forensics.CEO Harry Simeonidis emphasized the significance of this milestone and the company's readiness to transform the drug screening market. The system's ability to detect drugs within 10 minutes positions INBS for potential revenue growth and market expansion in one of the world's largest drug screening markets.